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Abstract We report the molecular analysis of the transthyretin 
gene in a large Italian pedigree with familial amyloidotic polyneu- 
ropathy and demonstrate the presence of a Met 3° mutation. The 
usefulness of the genetic analysis in the identification of presymp- 
tomatic persons and the diagnosis of individuals with partial 
symptoms is discussed. 
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I. Introduction 
the individuals described in the previous ection (IV-15, IV-25, IV-24, 
IV-19 and V-23, V-30, IV-31 and V-31) and was amplified by polym- 
erase chain reaction (PCR) using two 22 bases long oligonucleotide 
primers complementary to intronic sequences flanking TTR exon 2, 
5"-CGCTCCAGATTTCTAATACCAC-3" and 5'-AGTGAGGGGC- 
AAACGGGAAGAT-3' [10]. Reaction mixtures containing 25 ng of 
template and 5 pmol of each primer were amplified using Gene Amp 
PCR core kit (Perkin-Elmer Cetus). The first cycle was 95°C for 3 min, 
56°C for 30 s, 72°C for 1 min and subsequent cycles were at 95°C 
for 1 min, 56°C for 30 s, 72°C for 1 min with a final extension step 
at 72°C for 5 min. After thirty cycles of amplification the yield of PCR 
product containing exon 2 was approximately 20 ,ug/ml of DNA. Ap- 
proximately 300 ng of PCR product DNA was digested overnight with 
ten units of NsiI enzyme at 37°C, fractionated by electrophoresis 
through a 1.7% agarose gel and bands were visualized by ethidium 
bromide staining. 
Familial amyloidotic polyneuropathy (FAP) is an autosomal 
dominant disorder characterized by extracellular deposition of 
mutated protein fibrils, such as transthyretin (TTR), apolipo- 
protein A I and gelsolin [1,2]. FAP associated with mutations 
in the plasma TTR gene is the most frequent form [3]. Defined 
mutations in individual exons have been correlated with clinical 
presentations in several ethnic groups, including Italian families 
[4~8]. A new large Italian pedigree in the province of Molise was 
characterized clinically and pathologically [9]. Nineteen indi- 
viduals were affected in six generations and presented with 
peripheral sensory neuropathy involving the lower extremities, 
dysautonomia, cardiopathy and variable presence of ocular 
involvement and nephropathy. Furthermore two individuals 
presented with only dysautonomia and one with scalloped pu- 
pils. 
We report the molecular analysis of the transthyretin gene 
in this Italian pedigree with familial amyloidotic polyneuropa- 
thy and demonstrate the presence of a Met 3° mutation. The 
usefulness of the genetic analysis in the identification of pre- 
symptomatic persons and the diagnosis of individuals with par- 
tial symptoms is discussed. 
2. Materials and methods 
2.1. Patients 
The FAP family studied is a large kindred with nineteen affected 
individuals in six generations (Fig. 1). The clinical features and pa- 
thological characterization have been reported [9]. Two affected per- 
sons IV-25 (propositus) and IV-15 have biopsy proven endoneurial 
deposition of amyloid. Blood samples were obtained from IV-25 and 
IV- 15, two individuals with only dysautonomia (IV-24 and IV- 19), one 
with scalloped pupils (V-23) and three clinically asymptomatic individ- 
uals (V-30, IV-31 and V-31). 
2.2. DNA isolation and amplification 
Genomic DNA was extracted from peripheral blood white cells of 
*Corresponding author. Fax: (39) (51) 248862. 
2.3. DNA sequencing 
Sequence analysis was done using the AmpliTaq cycle sequencing kit 
(Perkin-Elmer Cetus). Prior to sequencing the PCR product DNA was 
purified through Qiaquick spin PCR purification kit (Qiagen) to re- 
move nucleotides and primers. Hundred fmol of template were an- 
nealed with 1.6 pmol of one of the primers used for amplification that 
was end labeled with 50 pCi of [y-33p]ATP (3,000 Ci/mmol, Dupont/ 
NEN). Sequencing products were separated through a 6% acrylamide, 
8 M urea gel and bands were visualized by autoradiography. 
3. Results and discussion 
This pedigree shows an autosomal dominant pattern of in- 
heritance (Fig. 1) and clinical features imilar to those described 
for FAP associated with mutations in TTR exon 2 [1,11]. The 
hallmark of the disease in this family is the presence of a periph- 
eral neuropathy starting in the lower extremities with sensory 
and autonomic involvement and severe cardiac dysfunction. 
Variability in clinical expressivity in the affected individuals 
was noted as well as the presence of partial symptomatology 
in three individuals who are siblings of affected members [9]. 
Sequence analysis of exon 2 PCR amplified DNA showed 
both G and A at nucleotide position 79 in an affected (IV-15) 
and a presymptomatic (V-30) individual (Fig. 2). The transition 
of G to A causes a Val to Met mutation at position 30 and both 
individuals are heterozygous for Val 3° and Met 3°. Since the G 
to A transition creates a new NsiI restriction site, the mutated 
allele can be identified by digestion of exon 2 DNA with NsiI. 
The mutation in two affected and a presymptomatic individual 
was confirmed with this analysis (Fig. 3). After digestion of 
exon 2 PCR amplified DNA with NsiI two bands of 165 and 
112 bp respectively were generated in addition to the normal 
uncut allele of 277 bp. PCR products from DNA of two individ- 
uals with only dysautonomia nd one with scalloped pupils 
(IV-19, IV-24 and V-23) did not show the mutation after diges- 
tion with NsiI (Fig. 4). 
Thus the Val to Met 3° mutation is associated with the disease 
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Fig. 1. Pedigree of an Italian kindred with autosomal dominant familial amyloidotic polyneuropathy. Affected individuals are designated by black 
symbols. All the individuals in generation IV had full neurological nd ophthalmological examinations a well as electrophysiological studies; IV-25 
and IV-15 have biopsy proven endoneurial deposition of amyloid. No data are available for generation I. 
in the affected members of this family and in a presymptomatic 
individual who has inherited the mutation from the mother 
(Fig. 1). He is only 32 years old and has not yet developed 
clinical signs of the disease that begins in the early forty's in this 
branch of the family [9]. By contrast, two individuals who 
presented with only dysautonomia and one with scalloped pu- 1 ) 
pils did not carry the mutation. This shows the importance of 
the molecular analysis in families with FAP. The two individu- 
als with only dysautonomia have affected siblings and could - \  
have been carriers of the mutation but not have developed the 
full blown clinical syndrome. Given the great clinical heteroge- 
neity in organs involvement, age of onset and duration of FAP 
[12], the diagnosis of this disease based exclusively on clinical 
grounds is difficult and requires identification of the mutation 
at the DNA level. 
Thirteen Italian families with a clinical presentation consis- 
tent with FAP have been reported. Seven families, including 
ours carry the Met 3° mutation whereas the remainder carry 
different mutations in exons 2 and 3 [4-7]. The prevalence or 
the Met 3° mutation in the Italian pedigrees is not surprising, 
since this is the most frequently found mutation in various 
ethnic backgrounds [13-14] and reflects the high mutation rate 
at CpG islands where the C is methylated and then converted 
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Fig. 2. Val to Met 3° mutation in exon 2: sequence analysis of PCR 
amplified exon 2 from DNA of individuals V-30 (1) and IV-15(2) 
showing the G to A transition at nucleotide 79. 
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Fig. 3. Agarose gel electrophoresis of PCR amplified exon 2 from 
genomic DNA of the propositus IV-25 (lanes 2-3), an affected individ- 
ual IV-15 (lanes 4-5) and a presymptomatic individual V-30 (lanes 6-7) 
before and after digestion with NsiI respectively. Lanes 1 and 8 are 
MspI cut pBR322 markers. Bands are visualized by ethidium bromide 
staining. After NsiI digestion two bands of 165 and 112 nucleotides are 
generated from the mutated allele, while the uncut exon is 277 nucleo- 
tides in length. 
to T by deamination [15]. The G of the Val codon is part of such 
CpG island and thus is a mutation 'hot-spot'. In summary, we 
report the molecular analysis of the TTR gene in this new 
Italian family and demonstrate the presence of a Met 3° muta- 
tion. In addition this study emphasizes the usefulness of the 
genetic analysis in the identification of presymptomatic persons 
and characterization of individuals with partial clinical symp- 
toms. 
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